野村的研究报告指，中生制药(01177.HK) 去年业绩不如预期，而完成了数个附属公司的出售应可令2025年的财务表现更一致及可比，今年增长指引达双位数。公司去年下半年收入按年增9%，经常性盈利按年增55%。以板块划分的话，去年下半年肿瘤科药物、止痛药以及呼吸道药物分别录得销售53.7亿元人民币、18.7亿元人民币以及13.7亿元人民币，按年增24.5%、6.5%及7.3%，而肝炎药物销售按年跌8.4%至14.1亿元人民币。该行将目标价由6.42港元降至5.52港元，评级“买入”。(vc/u)
(港股报价延迟最少十五分钟。沽空资料截至 2025-03-20 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.